Brief: Neurovive Resolves On Rights Issue Of SEK 123.8 Mln

Abliva AB

10/12/2018 07:36

Dec 10 (Reuters) - NeuroVive Pharmaceutical AB  NVP.ST :
    * NEUROVIVE RESOLVES ON A RIGHTS ISSUE OF MSEK 123.8 FOR
CONTINUED
DRUG DEVELOPMENT, AND NEW PUBLICATION DATE OF THE 2018 YEAR END
REPORT
    * SUBSCRIPTION PRICE IS SEK 1.35 PER SHARE
    * SUBSCRIPTION PERIOD RUNS FROM 23 JANUARY - 6 FEBRUARY 2019

Source text for Eikon:  ID:nWkr2Y9Fph 
Further company coverage:  NVP.ST 

 (Gdynia Newsroom)
 ((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))